As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
Researchers say simple blood-test and echocardiography pathway could reshape diabetes-related cardiovascular care
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Call it a major breakthrough for diagnostic imaging
Subscribe To Our Newsletter & Stay Updated
